Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Profermin
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Profermin (also marketed as ReFerm) is a postbiotic product developed for the dietary management of gastrointestinal and liver disorders, particularly ulcerative colitis (UC). It is a food for special medical purposes (FSMP) consisting of oat gruel fermented with the probiotic bacterium *Lactobacillus plantarum* 299v, along with barley malt and lecithin. As a postbiotic, it contains the metabolic byproducts of the fermentation process, which are thought to provide therapeutic benefits even in the absence of live bacteria. Profermin acts by modulating the gut microbiota and strengthening the intestinal epithelial barrier, thereby reducing paracellular permeability and inflammation. Clinical trials have demonstrated its efficacy in inducing remission in patients with mild-to-moderate active ulcerative colitis, and it has also been investigated for its potential to improve colonic barrier function in irritable bowel syndrome (IBS) and to halt disease progression in alcoholic liver disease.
- Brand names
- ProferminReFerm
- Other names
- ReFermfermented oat gruel
Beyond the preview
Go deeper on Profermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Profermin.